Form 8-K - Current report:
SEC Accession No. 0001193125-21-000213
Filing Date
2021-01-04
Accepted
2021-01-04 07:06:00
Documents
14
Period of Report
2021-01-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d34379d8k.htm   iXBRL 8-K 33220
2 EX-99.1 d34379dex991.htm EX-99.1 13835
6 GRAPHIC g34379g0104061944121.jpg GRAPHIC 4000
  Complete submission text file 0001193125-21-000213.txt   182956

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cala-20210104.xsd EX-101.SCH 3072
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cala-20210104_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cala-20210104_pre.xml EX-101.PRE 11409
7 EXTRACTED XBRL INSTANCE DOCUMENT d34379d8k_htm.xml XML 3377
Mailing Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080
Business Address 343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO CA 94080 650-870-1000
Calithera Biosciences, Inc. (Filer) CIK: 0001496671 (see all company filings)

EIN.: 272366329 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36644 | Film No.: 21500138
SIC: 2834 Pharmaceutical Preparations